Tissue Regenix Group PLC Directorate Change (9693G)
20 March 2020 - 6:00PM
UK Regulatory
TIDMTRX
RNS Number : 9693G
Tissue Regenix Group PLC
20 March 2020
Tissue Regenix Group plc
Directorate Change
Leeds, 20 March 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or the "Company"), the regenerative medical devices
company, announces that John Samuel, Executive Chair, has informed
the Board of his intention to step down from both that role and as
a board member after 12 years with the Company.
The Board have appointed Jonathan Glenn, a current non-executive
director of Tissue Regenix, to the position of non-executive Chair
on an interim basis with immediate effect. Most recently Jonathan
was CEO of Consort Medical from 2007 until its recent acquisition
by Recipharm AB, and has strong operational experience in the
sector. The Board will review the position of Chair in due course
and further announcements will be made at the appropriate time.
Randeep Grewal, Chair of the Nomination Committee, commented:
"On behalf of the Board I would like to thank John for his
commitment and contribution to the Company over many years. John
has been pivotal in building the Company from a small start-up to
its present form.
I am pleased to welcome Jonathan Glenn to the position of
interim Chair. Jonathan brings with him a deep understanding of the
healthcare industry and experience in leading companies through
successful growth phases. Jonathan's knowledge and leadership will
be increasingly valuable as we look to secure the next stage of our
commercial development."
For more Information:
Tissue Regenix Group plc Tel: 0330 430 3073
Caitlin Pearson Head of Communications
--------------------------------------------- --------------------
Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710 7600
Adviser and Broker)
Jonathan Senior / Alex Price / Ben Maddison
--------------------------------------------- --------------------
FTI Consulting Tel: 0203 727 1000
Simon Conway / Victoria Foster Mitchell
/ Mary Whittow
============================================= ====================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAPPUUGWUPUUQU
(END) Dow Jones Newswires
March 20, 2020 03:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024